Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.640
-0.260 (-28.89%)
At close: Nov 20, 2024, 4:00 PM
0.675
+0.035 (5.45%)
After-hours: Nov 20, 2024, 7:59 PM EST
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for LCTX stock have an average target of 4.75, with a low estimate of 2.00 and a high estimate of 7.00. The average target predicts an increase of 642.19% from the current stock price of 0.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LCTX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +212.50% | Nov 20, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +368.75% | Nov 18, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +525.00% | Aug 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +993.75% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +993.75% | Mar 8, 2024 |
Financial Forecast
Revenue This Year
5.32M
from 8.95M
Decreased by -40.48%
Revenue Next Year
11.90M
from 5.32M
Increased by 123.52%
EPS This Year
-0.13
from -0.12
EPS Next Year
-0.15
from -0.13
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.0M | 26.7M | 58.7M | ||
| Avg | 5.3M | 11.9M | 25.7M | ||
| Low | 2.8M | 2.0M | 3.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -10.8% | 400.9% | 393.2% | ||
| Avg | -40.5% | 123.5% | 116.1% | ||
| Low | -68.2% | -63.2% | -72.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.01 | -0.07 | -0.03 | ||
| Avg | -0.13 | -0.15 | -0.16 | ||
| Low | -0.18 | -0.24 | -0.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.